The Obesity Drug Development Summit Europe is your perfect platform to be in a prime position to be at the forefront of this ...

The Synthetic Human Genome (SynHG) Project, launched on the 25th anniversary of the mapping of the human genome, is being ...

The NNF – a philanthropic non-profit organisation that owns a controlling stake in Danish drugmaker Novo Nordisk – has been ...

The European Commission has cleared the high-strength formulation of Eylea (aflibercept) with an extended treatment interval ...

The CDC's newly constituted Advisory Committee on Immunization Practices (ACIP) has voted to recommend the removal of vaccine ...

It has been reported that Novo Nordisk may have inadvertently allowed generics of its GLP-1 agonist semaglutide, the active ...

Success in this area means ensuring the right therapy reaches the patient in a form that is stable, effective, and ready for ...

The UK is studying cases of pancreatitis in people taking drugs based on GLP-1 receptor agonists for weight loss or type 2 ...

Antisense-based therapy salanersen (BIIB115/ION306) is a possible follow-up to Biogen's big-selling Spinraza (nusinersen) ...

To close the innovation-access gap, there is a desperate need for an infrastructure rooted in trust. That means complementing ...

An alternative to epinephrine autoinjectors that can be delivered by a nasal spray has been launched in Germany, its first ...

It is not clear how AS01 might help lower the risk of dementia, but Oxford University said lab studies show that the adjuvant ...